// App-Quantinova.ai

14960 : Empagliflozin Reduces the Total Burden of Cardiovascular Events Including Recurrent Events in the EMPA-REG OUTCOME Trial

Researchers

Presenter

  • David H Fitchett

Principal Investigators

  • Silvio E Inzucchi

  • Bernard Zinman

  • Christoph Wanner

  • Stefan D Anker

  • Stuart Pocock

  • Stefan Kaspers

  • Jyothis T George

  • Odd Erik Johansen

  • Waheed Jamal

  • Stefan Hantel

  • Sren S Lund

Medical Centers

  • St. Michael's Hospital, Division of Cardiology, University of Toronto, Toronto, Canada

  • Section of Endocrinology, Yale School of Medicine, New Haven, CT

  • Lunenfeld-Tanenbaum Research Institute of Sinai Health System, University of Toronto, Toronto, Ontario, Canada

  • Würzburg Univ Clinic, Würzburg, Germany

  • Dept of Cardiology (CVK); and Berlin Institute of Health Cntr for Regenerative Therapies (BCRT); German Cntr for Cardiovascular Rsch (DZHK) partner site, Berlin, Germany

  • Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Boehringer Ingelheim Norway KS, Asker, Norway

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach, Germany

Locations

  • Canada

  • United States

  • Germany

  • United Kingdom

  • Norway

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Transient Ischemic Attack

  • Myocardial infarction

  • Angina

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • BI-10773

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved